Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

Novo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing. The FDA hasn't communicated a…

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketwatch.com)